Current Cardiovascular Risk Reports

, Volume 7, Issue 2, pp 102–107

Myeloperoxidase and Atherosclerosis

NOVEL AND EMERGING RISK FACTORS (N WONG AND C LEWIS, SECTION EDITORS)

DOI: 10.1007/s12170-013-0291-3

Cite this article as:
Kamanna, V.S., Ganji, S.H. & Kashyap, M.L. Curr Cardiovasc Risk Rep (2013) 7: 102. doi:10.1007/s12170-013-0291-3

Abstract

Myeloperoxidase (MPO), a member of the peroxidase family, emerged as a major player in the initiation and propagation of atherosclerotic cardiovascular disease (CVD). Evidence for its role in atherosclerosis include that MPO: a) induces endothelial dysfunction, b) modifies physiologically functional high density lipoprotein (HDL) into “dysfunctional HDL”, c) converts low density lipoprotein (LDL) into more atherogenic modified LDL form, and d) induces endothelial cell death and tissue factor expression involved in plaque vulnerability. Elevated levels of blood MPO are associated with CVD, predict incident risks for myocardial infarction and cardiac death in subjects with acute coronary syndrome, and predict future risk of coronary artery disease (CAD) in healthy individuals. In this article, we review current understandings on the role of MPO in pathophysiological processes involved in atherosclerosis and CVD.

Keywords

Myeloperoxidase Atherosclerosis Cardiovascular disease Coronary artery disease High density lipoproteins Low density lipoproteins Niacin Statins Inflammation Apolipoprotein AI Neutrophils 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California, and Department of MedicineUniversity of CaliforniaIrvineUSA
  2. 2.Atherosclerosis Research Center, Medical Research Service (09–151)Veterans Affairs Healthcare SystemLong BeachUSA

Personalised recommendations